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A novel class of competitive. acylating inhibitors for the proline-specific peptidases: dipeptidyl peptidase IV, dipeptidyl peptidase II and prolyl 
endopeptidase, has been developed. The inhibitor molecules combine the efficacy of aminoacyl pyrrolidides and the potential transacylating 
capability of diacyl hydroxyl amines. The N-terminal deblocked inhibitors are potent reversible inhibitors of porcine kidney dipeptidyl peptidase 
IV. human placenta dipeptidyl peptidase II exhibiting K, values in thepM range. Boc-protected (w-N-hydroxy acyl amid) aminodiacarboxylic acid 
pyrrolidides inhibit substrate hydrolysis by prolyl endopeptidases from different sources competitively reaching K, values of 30 nM to 60 PM. 
Additionally. cr-N-BOC-(w-N-hydroxy acetyl) glutaminyl pyrrolidide modifies human placenta prolyl endopeptidase in a time-dependent reaction. 
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1. INTRODUCTION 
Peptide bonds involving proline residues are fairly 
resistant to the action of endo- and exopeptidases with 
broader substrate specificity. These proline bonds are 
exposed cleavage points for proline-specific peptidases 
(Scheme 1). Thus, these enzymes seem to play an impor- 
tant role in maturation and degradation of peptide 
hormones and neuropeptides [ 1,2], and on the other 
hand they serve as invasion factors for numerous path- 
ogenic microorganisms [3,4]. Physiological processes as 
protein folding and signal transmission as well as unde- 
sirable processes like HIV maturation, caused by -X- 
Pro-specific aspartate protease, are related to the phys- 
ical properties of proline. Work dealing with mechanis- 
tic features of the proline-specific enzymes including 
inhibitor design is therefore of general interest [5.6]. 
Among these enzymes, prolyl endopeptidase (PEP) and 
dipeptidyl peptidase IV (DP IV) exhibit certain similar- 
ities in their catalytic behavior, i.e. similar rate con- 
stants for substrate hydrolysis, preference of proline 
over alanine in the P, position of similar substrates and 
drastic discrimination of other amino acids at the cleav- 
age site [7]. Recent studies suggest that PEP is an en- 
zyme involved in learning and memory process [8]. Pos- 
sibly, it could be involved in the generation of the j?- 
amyloid A4 peptide in Alzheimer’s disease [9, lo]. DP IV 
seems to be involved in signal transmission during the 
immune response [ 11-l 31. 
To perform detailed investigations of the physiologi- 
cal role of regulatory peptides, stable, specific and selec- 
tive inhibitors are useful tools. Our studies on mecha- 
nism-based protease inhibitors show that, in contrast to 
other serine and cysteine proteases which are inac- 
tivated efficiently by N-peptidyl-0-acyl hydroxylam- 
ines, PEP and DP IV mainly hydrolyze these com- 
pounds as substrates [1416]. 
Proline-containing peptide aldehydes [ 171 and 
boronic acids [3] have been tested as inhibitors of pro- 
line-specific peptidases, but their instability due to the 
reactive electrophiles within their structures should limit 
their potential to be used in biological systems. Both 
enzyme types are inhibited by diisopropylfluoro- 
phosphate (DFP) and DEP and have been characterized 
to be serine proteases [2,7,18]. In contrast to the bacte- 
rial enzymes, vertebrate PEPS have sensitive thiol resi- 
dues in or near their active site [19]. 
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Hauzer and co-workers [19] showed that the natural 
substrates of PEP, the intramolecular disulfide- 
bridged peptide hormones oxytocin (OT: 
Cys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH,) and vaso- 
pressin (VP: Cvs-Tyr-Phe-Gln-Asn-Cys-Pro-Arg- Gly- 
NH,) are already inhibitors of the enzyme. The mecha- 
nism of the inactivation suggested is a thiolldisulfide 
exchange between the substrate and a thiol group in/ 
near the active site of vertebrate PEP. 
Since N-peptidyl, 0-acyl hydroxylamines are known 
Published by Elsrvier Scirncr Publishers B. V. 23 
Volume 320, number I FEBS LETTERS March 1993 
Proline lminopeptidase HIV-Protease 
DP II, DP IV PEP Proline Carboxypeptidase 
I:=R171-.IX.II; 
PI.0 PI-0 
t r 
Aminopeptidase P Prolyl Carboxypeptidase 
I 
Prolidase Prolinase 
Scheme I Substrate specificity of proline-specific peptidases. 
to be effective and selective inhibitors of thiol-depend- 
ent enzymes [I 51, we anticipated a potential modifica- 
tion of the active site thiol group of vertebrate PEP 
incorporating the inhibiting -NH-O-acyl-moiety into a 
substrate analog structure. 
2. MATERIALS AND METHODS 
2.1. General, synthesis and product analysis 
All reagents for synthesis were purchased from commercial sources 
and, in the case of solvents, dried using common procedures. a-N- 
BOC-, w-OMe aminodicarboxylic acid pyrrolidides were obtained 
according to known standard procedures as described in [14,20]. The 
products were transformed into the appropriate hydroxamic acids by 
treatment of the corresponding methyl esters with 3.5 M hydroxylam- 
ine in a methanol solution followed by acetylation or benzoylation 
according to [14]. After purification and characterization of the inhib- 
itors for the PEPS (compounds 14, Table I), the N-terminal depro- 
tected inhibitors of the dipeptidyl peptidases (compounds 5-8, Table 
I) were obtained by removing the BOC groups in I.1 N HCl/glacial 
acetic acid for 30 min and washing of the products using diethyl ether. 
After drying and recrystallization the purity of the products was 
checked by HPLC. The structures and molecular weights were con- 
firmed by “C NMR, mass spectroscopy and elemental analysis. 
HPLC analysis of all compounds was performed using a Merck- 
Hitachi system equipped with a photodiode array detector. 13C NMR 
spectra were recorded on a Bruker WP-200 spectrometer. Mass spec- 
tra were taken in positive mode on a FISONS VG-BIO-Q triple quad- 
rupole tandem mass spectrometer equipped with an electrospray at- 
mospheric pressure LC interface (Manchester, UK). Data were ac- 
quired and processed on a Intel-486 personal computer system. 
2.2. Enrymes and substrates 
Preparation of substrates has been described previously [7, I I, 181. 
DP IV from pig kidney and PepX from Lactococcus lactis were pre- 
pared according to earlier work [14,21]. The specific activity using 
H-Gly-Pro-4-NA as substrate was 33.1 U/mg and 12.7 U/mg, respec- 
tively. Dipeptidyl peptidase II (DP II) from human placenta was a gift 
of Dr. J. Rahfeld, Max-Planck-Research Group, Halle (Saale) and 
exhibited a specific activity of 8.2 U/mg using H-Ala-Pro4-NA as 
substrate. 
PEP from Flavobacterium meningosepticum (PEP bact.) was from 
Miles, USA. PEP from pig brain (PEP port.) was purified according 
to [25]. PEP from human placenta (PEP hum.) was purified to homo- 
geneity using a slightly modified preparation protocol [25]. The spe- 
cific activities using Sue-Ala-Pro-4-NA as a substrate [25] were 14.5, 
24.7 and 3.1 Ulmg, respectively. 
2.3. Kinetic measurements 
The activity of the PEPS and the dipeptidyl peptidases DP IV and 
PepX was analyzed at 30°C in 0.04 M sodium phosphate buffer, pH 
7.6, ionic strength of 0.125. DP II, according to its acid activity opti- 
mum, was investigated in 0.04 M sodium acetate buffer, pH 5.5. 
Enzyme-catalyzed hydrolysis of the substrates succinyl-alanyl-prolyl- 
4-nitroanilide and H-glycyl-prolyl-4-nitroanilide by the PEPS and the 
dipeptidyl peptidases, respectively, was analyzed on a Kontron Uvi- 
con 630 UV-vis spectrophotometer. Estimation of the inhibition con- 
stants K, was performed according to Dixon, essentially as described 
in [7,25]. The progress curves for the inhibition of PEPS in the presence 
of substrate were monitored using succinyl-glycyl-prolyl-4-methyl-7- 
coumarylamide (Sigma) as a substrate at 30°C in 0.04 M tricine 
buffer, pH 7.6, ionic strength of 0.125, on a Kontron SFM 25 fluori- 
meter using 383 nm as excitation and 450 nm as emission wavelength. 
The pseudo-first order rate constants of the time-dependent decrease 
in the enzyme activity were calculated by applying non-linear regres- 
sion programs to the fluorescenceetime values as described in [14,15]. 
2.4. Stability of the inhibitors 
Incubation of the compounds in test buffer solution at 30°C over 
a time period of up to 24 h and proving the integrity of the products 
using UV-spectroscopy and HPLC indicated no significant decompo- 
sition of the inhibitors within the first 4 h of incubation time. Addition- 
Table I 
Analytical data of (w-N(O-acyl) hydroxyamid) aminodicarboxylic acid pyrrolidides 
No. Inhibitor Mol. wt. MS (M+H)** Fp. (“C)* HPLC-R, (min)** 
I BOC-Glu(NHO-Bz) Pyr 419.20 420.96 
2 BOC-Asp(NHO-Bz) Pyr 405.19 406.02 
3 BOC-Glu(NHO-AC) Pyr 357.19 357.99 
4 BOC-Asp(NHO-AC) Pyr 343.17 344.09 
5 H-Glu(NHO-Bz) Pyr/HCl 354.81 319.41 
6 H-Asp(NHO-Bz) Pyr/HCl 340.78 305.09 
7 H-Glu(NHO-AC) PyrlHCl 292.74 257.18 
8 H-Asp(NHO-AC) Pyr/HCl 278.72 244.53 
I58 19.62 
I38 19.01 
124 14.48 
II6 14.59 
140 17.84 
136 17.29 
137 9.11 
oil 8.76 
*Uncorrected values. 
**Retention time (R,-) on a SERVA HPLC-column; Si 100; 5 x 200 mm; IO pm particle size; solvent system, acetonitrile/water containing 0.04% 
trifluoroacetic acid gradient, 20-80% acetonitrile in 20 min; flow rate, 0.5 ml/min. 
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Fig. 1. Progress curves of the PEP-catalyzed hydrolysis of succinyl-glycyl-prolyl-4-methyl-7coumarylamide in the presence of different concentra- 
tions of the inhibitor BOC-Glu(NH-0-Ac) pyrrolidide. v’, 4.68 PM; l , I .56 M; n , 0.52 M. Sue-Gly-Pro-MCA was 35 ,LLM (see section 2). 
ally, no significant loss of the inhibitory potency of solutions of H- 
Glu(NHO-Bz) pyrrolidide and BOC-Glu(NHO-Bz) pyrrolidide 
against DP IV and PEP port. during the first 4 h of incubation was 
observed, confirming the above result. The release of the benzoic acid 
residue from H-Glu(NHO-Bz) pyrrolidide and H-Asp(NHO-AC) pyr- 
rolidide was followed as described in [14] and resulted in pseudo-first 
order rate constants of the decomposition of 0.028 he’ and 0.044 h-‘. 
respectively. 
To demonstrate chemical modification of PEP from human pla- 
centa by BOC-Glu(NHO-AC) pyrrolidide the enzyme was incubated 
for 3 h with 2.6-69 ,uM inhibitor resulting in a residual activity of the 
enzyme of 3.5%. The solution was given to Centricell molecular filter 
tubes (Polyscience) of an exclusion molecular weight of 10.000 Da. 
Protein and inhibitor were separated by repeated centrifugation for I 
h at 5,000 rpm and washing with buffer solution. The activity of the 
protein solution and of controls was estimated as described above. 
3. RESULTS AND DISCUSSION 
Mimicking the parts of the molecules of oxytocin 
(OT) and vasopressin (VP) responsible for substrate 
recognition and enzyme inhibition we analyzed several 
cl-N-BOC-(w-N-( 0-acyl) hydroxyamid) aminodiacar- 
boxylic acid pyrrolidides of the following structure as 
potential inhibitors of proline-specific enzymes (Scheme 
2). 
Since aminoacyl pyrrolidides and thiazolidides are 
known to be potent reversible inhibitors of PEP and DP 
IV [22-241, we used aspartyl pyrrolidide and glutamyl 
pyrrolidide as basis compounds for further inhibitor 
design. We attached an 0-acyl hydroxylamine residue 
to the carboxyl side chain functionality of the amino 
acid in position P7, hoping that interaction of the hy- 
droxylamine linkage would lead to a chemical reaction 
[22] if positioned near the active site thiol group during 
non-covalent binding of the inhibitor to vertebrate PEP. 
Since no crystal structure of any of the proline-spe- 
cific peptidases is available on which to perform some 
initial theoretical design, we varied the length and size 
of the side chain by using glutamic or aspartic acid in 
position P? and acetyl (AC) and benzoyl (Bz) groups as 
0-acyl residues (Table I). The synthesized compounds 
were tested as competitive inhibitors of three PEPS and 
three dipeptidyl peptidases from different sources. 
Table II lists the inhibition constants of the non-cova- 
lent E . I complexes formed. The inhibition is, in all but 
one case, competitive and reversible. The inhibitors are 
among the most potent and stable reversible inhibitors 
of their target enzymes. 
While the inhibitory activity of the 4 inhibitors tested 
is almost identical for the dipeptidyl peptidases, the 
PEPS from various organisms interact with their effec- 
OXYTOCIN, VASOPRESSIN INHIBITOR 
- Cy5 - Pro . 
BOC-+H 
I 
AC /O 
Scheme 2. Substrate and inhibitor structures. 
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Fig. 2. Progress curve of the PEP-catalyzed hydrolysis of succinyl-glycyl-prolyl-4-methyl-7-coumarylamide (35 ,uM) in the presence of 2.58 ,uM 
BOC-Glu(NH-O-AC) pyrrolidide (v) and progress curve (0) of the PEP-catalyzed hydrolysis of succinyl-glycyl-prolyl-4-methyl-7-coumarylamide 
(35 PM) after separation of the inhibited enzyme from excess inhibitor by ultrafiltration and repetitive incubation by 2.58 PM BOC-Glu- 
(NHO-O-AC) pyrrolidide (see section 2). 
tors remarkably differently. PEP bact. (Fluvohucterium 
meningosepticum) and PEP hum. (human placenta) are 
discriminated for by more than 3 orders of magnitude 
by BOC-Glu(NHO-Bz) pyrrolidide. This result might 
reflect greater differences in the spatial structure around 
the active site of the enzymes. Generally, hydrophobic 
residues attached to the side chain of the amino acid in 
position P, increase the affinity between enzyme and 
inhibitor in both groups of peptidases. In contrast to the 
dipeptidyl peptidases and the bacterial PEP the verte- 
bral PEPS are known to be sensitive towards thiol mod- 
ifying reagents [7,19,25]. This reactive thiol group, 
thought to be located near the active site, might serve 
as target in inhibitor design. 
For one of the two vertebrate enzymes tested, we 
found the anticipated time-dependent loss of activity of 
the target enzyme applying our potential modifying rea- 
gents. Incubation of PEP hum. with BOC-Glu(NH-O- 
AC) pyrrolidide in the presence of substrate led also to 
an inhibitor concentration-dependent decrease of the 
enzyme activity (Fig. I). Analyzing this time-dependent 
reaction (see [ 14,151) using an inhibitor concentration 
range of 20 nM_70 PM we found a maximum rate 
constant of k = 4.0 10e4 sY’ and an apparent binding 
constant of K, = 28 nM. 
Three possible mechanisms could explain the effect: 
(i) slow binding inhibition, (ii) chemical modification of 
the inhibitor (after binding to the target protein) result- 
ing in higher affinity of the modified inhibitor to the 
enzyme, or (iii) chemical modification of the enzyme by 
26 
the inhibitor resulting a new enzyme species with modi- 
fied kinetic properties. 
Separation of the inhibited enzyme from excess inhib- 
itor by ultrafiltration did not restore the full activity of 
the inhibitor-treated enzyme. Incubating PEP hum. 
with BOC-Glu(NH-O-AC) pyrrolidide and extensive fil- 
tration and washing yielded only partially (up to 62%) 
reactivated enzyme. Incubation of this enzyme with 
fresh inhibitor solution did not result in a reproducible 
time-dependent loss of activity, as shown in Fig. 2. 
Table II 
Inhibition constants (K, in PM) of proline-specific peptidases by 
(w-N(U-acyl) hydroxyamid) aminodicarboxylic acid pyrrolidides 
Inhibitor 
I 
2 
3 
4 
PEP bact. 
Il.7 
21.5 
49.5 
59.2 
Enzyme 
PEP port. 
0.1 
5.4 
13.8 
25.6 
PEP hum. 
0.03 
0.5 
1.5 
2.8 
DP IV 
1.0 
4.2 
13.0 
24.0 
PepX 
2.2 
I .9 
22.8 
DP 11 
3.8 
4. I 
29.9 
40.9 
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Proposed inactivation mechanism of PEP 
by Boc-Glu(NHO-AC)-Pyrrolidide 
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Scheme 3. Proposed inactivation mechanism of PEP by BOC- 
Glu(NH-O-AC) pyrrolidide. 
From this result we propose that, during interaction 
of PEP hum. with BOC-Glu(NH-O-AC) pyrrolidide, 
modification of the target protein occurs. The following 
sequence of events might explain the observed effect 
(Scheme 3): (i) substrateeanalog binding of the inhibitor 
into the active site of PEP hum.; (ii) deprotonation and 
activation of the thiol group by the negatively charged 
hydroxyamide group; (iii) nucleophilic attack of sulfur 
on the carbonylcarbon of the O-acetyl residue; (iv) 
transacylation of the acetyl residue to the enzyme form- 
ing a thiolester derivative. 
Currently the structure of the enzyme-inhibitor com- 
plex formed and other modifying attachments to the 
competitive inhibitors are under investigation. 
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